Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($1.18), $0.45 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $277 thousand versus the consensus estimate of $210 thousand.

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.